Cargando...
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
Several ongoing clinical trials are investigating the use of immuno-targeting therapy with programmed cell death protein-1 and programmed death-ligand 1 (PD-L1) inhibitors for triple-negative breast cancer. However, the role of PD-L1 expression in HER2-positive breast cancer remains unclear. We inve...
Guardado en:
| Publicado en: | Sci Rep |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6853939/ https://ncbi.nlm.nih.gov/pubmed/31723167 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-52944-6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|